News - Appointments

Sylvie Ryckebusch has joined the board of directors of Domain Therapeutics SA, a Franco-Canadian biotech specialising in allosteric modulators and biased ligands for developing products for Parkinson’s disease and a range of cancers.

ReViral Ltd, a developer of antiviral compounds to treat respiratory syncytial virus (RSV), has named Alex C. Sapir as chief executive, replacing Eddy Littler who assumes the post of chief operating officer.

Belgian biotech eTheRNA Immunotherapies NV, that uses messenger RNA to treat cancers, has hired Ulrich Platte as chief financial officer.

Valo Therapeutics Ltd, a UK spinout from the University of Helsinki, Finland with a novel approach for vaccinating against cancers, has named Michael Stein as chief executive.

Jan Ohrstrom is assuming the role of chief executive in addition to his current position as board chairman of the French biotech, Biom’up SA.

The UK biotech OMass Therapeutics Ltd has appointed Rosamond Deegan as its chief executive officer to manage its high-resolution mass spectrometry platform for drug discovery.

Novigenix SA has named Jan Groen as chief executive to help lead the company’s commercialisation of products for early cancer detection. The Swiss company’s technology involves identifying disease specific mRNA signatures in circulating immune cells.

Harald Hampel, an expert in neurodegenerative diseases, has been appointed head of global medical affairs at Eisai Inc to oversee the company’s Alzheimer’s disease and dementia research.

Mohammed Dar, formerly of AstraZeneca Plc, has joined the UK biotech Immunocore Ltd as chief medical officer and head of clinical development to manage the company’s portfolio of T cell receptor therapies.

Christian Meisel has joined the German diagnostics company Molecular Health GmbH as chief medical officer to oversee development of the company’s tools for precision medicine.